Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eribulin Mesylate
Eribulin Mesylate
Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
BusinessWire
Sun, 06/6/10 - 12:31 pm
Eisai
Eribulin Mesylate
breast cancer
